<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="811">
  <stage>Registered</stage>
  <submitdate>4/10/2005</submitdate>
  <approvaldate>6/10/2005</approvaldate>
  <actrnumber>ACTRN12605000604606</actrnumber>
  <trial_identification>
    <studytitle>Launceston chickpea extended ad libitum consumption study</studytitle>
    <scientifictitle>A cross-over trial of the effect of ad libitum supplementation of chickpeas in the diet on nutrient intake, physiologic or metabolic parameters, compared to an ad libitum diet only for the reduction in cardiovascular disease risk factors</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular disease risk</healthcondition>
    <healthcondition>Glucose intolerance</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sequential cross-over trial comparing the effects of a stated minimum amount of chickpeas per week (four 300g cans) with an unrestricted (usual) diet of the subject's choosing. Chickpea diet period was 12 weeks duration.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum lipid and lipoprotein levels</outcome>
      <timepoint>Measured at the end of 4 weeks of observed usual diet, at the end of 12 weeks of the ad libitum chickpea diet, and after a further 4 weeks on the usual diet (weeks 4, 16 and 20)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Plasma glucose levels</outcome>
      <timepoint>Measured at the end of 4 weeks of observed usual diet, at the end of 12 weeks of the ad libitum chickpea diet, and after a further 4 weeks on the usual diet (weeks 4, 16 and 20)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serum insulin levels</outcome>
      <timepoint>Measured at the end of 4 weeks of observed usual diet, at the end of 12 weeks of the ad libitum chickpea diet, and after a further 4 weeks on the usual diet (weeks 4, 16 and 20)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma homocystine levels</outcome>
      <timepoint>Results were measured at weeks 4, 16 and 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glutathione peroxidase levels</outcome>
      <timepoint>Results were measured at weeks 4, 16 and 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum leptin levels</outcome>
      <timepoint>Results were measured at weeks 4, 16 and 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antioxidant status and haematological parameters</outcome>
      <timepoint>Results were measured at weeks 4, 16 and 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Perceived degrees of satiety, perceived degrees of bowel health and function.</outcome>
      <timepoint>Results were measured at weeks 4, 16 and 20</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Middle-aged, healthy, recruited by newspaper advertisement who were willing to eat a chickpea supplemented diet for a 12 week period. </inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Those on lipid-lowering or anti-diabetic medication; intolerant to chickpea or wheat.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>School of Human Life Sciences, University of Tasmania</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Tasmania</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Grains Research Development Corporation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HUMAN RESEARCH ETHICS COMMITTEE (TASMANIA) NETWORK: Medical</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Madeleine Ball</name>
      <address>University of Tasmania
Locked Bag 1320
Launceston TAS 7250</address>
      <phone>+61 3 63245480</phone>
      <fax>+61 3 63243658</fax>
      <email>Madeleine.Ball@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Jane Pittaway</name>
      <address>University of Tasmania
Locked Bag 1320
Launceston TAS 7250</address>
      <phone>+61 3 63245495</phone>
      <fax>+61 3 63243658</fax>
      <email>Jane.Pittaway@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>